"Patients are willing to accept self-limited acute adverse effects associated with recovery” after brachytherapy and radical prostatectomy, according to the study authors. These effects “have been well documented for both modalities and are quite different. Late effects have been less well documented and, at the time of this study, never compared in a randomized trial,” the researchers pointed out. Because PSA screening has reduced the age at diagnosis of prostate cancer by a decade, long-term quality-of-life considerations are even more important in treatment choice, they commented. ■